| lergicrhinitis,AR) is a kind of nasal mucosa noninfectious inflammatory disease, which occurs after susceptibility residents contacting sensitization allergens,and it contains the release of inflammatory mediators mainly mediated by the IgE, many kinds of active immune cells,and inflammatory cells factor. Prevalence of Allergic rhinitis in worldwide is rising and in European and American countries,adult prevalence of allergic rhinitis is generally10%-25%.while,in our country recent years,the number of outpatient increased,and it affects seriously on the quality of life of the patients.However, there has been no method,which can effectively prevent and cure the disease so far,The whole body and local double ways of anti-allergy and anti-inflammatory treatment is the main ways to cure allergic rhinitis, the double treatment ways mainly including the whole body antihistamines (such as Cetirizine and loratadine) and local anti-inflammatory drugs to allergy (such as nasonex and budesonide) are most safety and effective. A new meta analysis suggests, mometasone furoate-nasonex can effectively reduce allergic rhinitis nasal symptom scores in total score and a single symptom score in allergic rhinitis patients, including nasal congestion. But drugs just symptomatic treatment, it can’t to maintain lasting curative effect after stopping drug.Allergen-specific immunotherapy is a way for some variation of allergen-sensitive patients to gradually increase the amount of the allergen product, thereby reducing symptoms when patients exposure to the allergen environment, which can induce clinical and immune tolerance, even if you stop treatment, it still has a long-term effect on the body and can prevent the further development of allergic disease, reducing the incidence of asthma,improving the quality of life of patients with allergic diseases after a period of time SIT. The principle of specific immunotherapy is the regulator of Thl and Th2immune response imbalance. Immunotherapy is the only course of treatment to change the development of disease. The quality for composition of the allergen product is very important for disease diagnosis and treatment prevention.Antuoda largest patient selection in the world and with the most documented immune therapeutic agents.Before and after treatment of allergic rhinitis drugs and alergen specific immunotherapy lack of objective indicators to evaluate the therapeutic effect in clinical work, patient complained of symptoms is still the main basis to evaluate the therapeutic effect and adjust the treatment plan. The of sub-level scoring criteria (such as nasal symptoms points total and individual symptom scoring) is widely used in the judgment of the severity of allergic rhinitis and clinical efficacy, clinical need, objective method to evaluate the treatment of allergic rhinitis, nasal resistance and nasal cellsthe examination is an objective method of assessing the severity of symptoms, and graded as symptoms of a supplementary scoring criteria.This article is in order to understand application value of nasal resistance and nasal cytology index changes before and after Allergen specific immunotherapy in evaluating the therapeutic effect and adjusting the treatment plan,for example, the severity and degree of remission for treatment of AR symptoms, was negatively correlated with nasal resistance, and the EOS, the ECP, With the subjective symptom scores and nasal pathology to evaluate the correlation. If you know the dynamic changes for AR patients in nasal resistance and nasal lavage fluid of EOS and ECP before and after the desensitization treatment of Antuoda,wecan Objectively know the contro of disease, provide guidance for the evaluation of clinical efficacy or adjust treatment, clearly imonitore the effect of evaluation of allergic rhinitis In nasal resistance, nasal lavage fluid in EOS and ECP.While the nasal resistance, nasal lavage fluid of EOS and ECP has little article in the clinical efficacy to determine the application.There is no repport about the application of nasal resistance and nasal lavage fluid of EOS and ECP to exam in drug treatment and Antuodan before and after the desensitization treatment of allergic rhinitis.1.To observe and compare the dynamic changes of Allergic rhinitis, nasal resistance and EOS of Nasal lavage fluid and ECP after and before desensitization therapy of antuoda.2. Nasal resistance and nasal secretions of EOS and ECP in allergic rhinitis judgment value.To Followe and trace with43cases of adult patients have2-14years of history with clinic symptoms as sneezing, nasal congestion, runny, nasal itching between January2009and May2011in Zhongshan Hospital ENTAll patients age range (17-46years) and average age (29±4.2years old),20males and23females who are in line with the2004Lanzhou meeting AR and the standards of severe allergic rhinitis,after Skinprick test,being identified asthe dust mite allergy,the result of prick≥++, thorn prick solution for the security of SQ, are provided by the Danish ALK.Change should be the original screening for house dust mites and dust mite allergy. All patients should comply with requirements that all patients are without medication contraindications and without rhinosinusitis response, Nasal polyps, nasal septum is a serious deviation, drug-induced rhinitis, allergy symptoms In other parts, such as asthma and so on, they had not received any drug treatment of allergic diseases during specific immunotherapy to carry out desensitization therapy.Age of control group ranges (17from46years) and average age (29±4.2years),4male,8female human are thyroid adenoma patients in our department.1To record before treatment history, nasal endoscopy, signs and symptoms score; nasal resistance and nasal lavage fluid eosinophils and eosinophil cationic protein value, and take a small amount of pathological examination of inferior turbinate2.To record score of signs and symptoms after15weeks of treatment, nasal resistance, eosinophil cationic protein value.of nasal lavage fluid.3.To.record score of signs and symptoms and nasal resistance and eosinophil cationic protein value.of nasal lavage fluid, and take a small amount of Inferior turbinate mucosa to check and carry out endoscopy.4. To analyze and compare whether there are differences in score of signs and symptoms, nasal resistance and EOS of nasal lavage fluid and the value of ECP, comparing pathological changes of bucosal and examination of nasal endoscopy after one year treatment.1.Quantitative data selects arithmetic mean±standard deviation (x(-)±s) to describe2. Two quantitative dataT were compared by using t-test, count data were compared by using the x2test;3.Analysis of the correlation between two variables using simple correlation or partial correlation;4.P<0.05of difference has statistically significant;5.The measured value index by SPSS13.0repeated measurement data analysis of variance and SAS9.2statistical software of the generalized estimating equations proc genmod step process to analyze. 1.The comparation nasal of resistance and total symptom score that immunotherapy group before treatment and after15weeks of treatment and after1year of treatment, total symptom score have significant difference (χ2=78.83, P<0.05), nasal of resistance also have significant difference (F=318.811, P<0.05)2. Nasal resistance before immunotherapy and the control group has significant difference in the immune therapy(P<0.05), nasal resistance after immunotherapy after one year contrarys to it(P>0.5).3. Before immunotherapy treatment and after treatment after15weeks and after1year of treatment ECP have significant difference (F=254.215P<0.05).4. ECP before immunotherapy has differens with the control group in statistics(P <0.05),ECP after immunotherapy of one year contrarys to it(P>0.5).5.Nasal resistance does not associated with the total symptoms score (P>0.5), ECP is the same(P>0.5).6. Eosinophils quantity of nasal secretion before immunotherapy treatment and after have significant difference (P<0.05).1. Nasal resistance before and after immunotherapy and EOS of nasal lavage fluid and ECP have improved obviously, which have not mattered with score of signs and symptoms.2. This research suggest the continuous dynamic testing of nasal resistance and nasal lavage fluid of EOS and ECP can judged the efficacy objectively and be as the supplement of signs and symptoms score. |
PDF Full Text Request